Neurogene to Participate in Stifel 2026 Virtual CNS Forum
NEW YORK–(BUSINESS WIRE)–
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum.
Format: Management will participate in a fireside chat
Date: Wednesday, March 18 at 9:00 a.m. ET
A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the event will also be available for a limited time.
About Neurogene
Neurogene (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260311342818/en/
Company Contact:
Mike Devine
Executive Director, Corporate Communications
[email protected]
Investor Contact:
Argot Partners
[email protected]
KEYWORDS: New York United States North America
INDUSTRY KEYWORDS: Health Neurology Genetics Research Science Pharmaceutical Biotechnology
MEDIA: